Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark A Boyd

Showing results (1-10 of 93) with videos related to

Pageof 10
Sort By:
Current Opinion in HIV and AIDS|June 18, 2009
Improvements in antiretroviral therapy outcomes over calendar timeMark A Boyd
The Lancet. HIV|June 4, 2017
Body composition substudy of the SECOND-LINE study - Author's replyMark A Boyd,
Current Opinion in HIV and AIDS|January 5, 2010
Current and future management of treatment failure in low- and middle-income countriesMark A Boyd
The Medical Journal of Australia|February 21, 2007
An unusual cause of severe metabolic acidosisMark A Boyd, Stephen Hedger
Lancet (London, England)|July 9, 2013
Antiretroviral therapy: dolutegravir sets SAIL(ING)Mark A Boyd, Basil Donovan
AIDS Research and Therapy|December 17, 2013
Antiretroviral regimens sparing agents from the nucleoside(tide) reverse transcriptase inhibitor class: a review of the recent literatureAmit C Achhra, Mark A Boyd
Lancet (London, England)|July 29, 2017
Long-acting injectable ART: next revolution in HIV?Mark A Boyd, David A Cooper
Lancet (London, England)|July 26, 2012
Optimisation of HIV care and service delivery: doing more with lessMark A Boyd, David A Cooper
Pharmacoeconomics|December 25, 2010
Clinical management of treatment-experienced, HIV/AIDS patients in the combination antiretroviral therapy eraMark A Boyd, Andrew M Hill
Lancet (London, England)|June 19, 2010
Operational research in HIV priority areas: the African wayMark A Boyd, Chidi A Nwizu
Pageof 10

Showing results (1-10 of 93) with videos related to

Sort By:
Pageof 10
Current Opinion in HIV and AIDS|June 18, 2009
Improvements in antiretroviral therapy outcomes over calendar timeMark A Boyd
The Lancet. HIV|June 4, 2017
Body composition substudy of the SECOND-LINE study - Author's replyMark A Boyd,
Current Opinion in HIV and AIDS|January 5, 2010
Current and future management of treatment failure in low- and middle-income countriesMark A Boyd
The Medical Journal of Australia|February 21, 2007
An unusual cause of severe metabolic acidosisMark A Boyd, Stephen Hedger
Lancet (London, England)|July 9, 2013
Antiretroviral therapy: dolutegravir sets SAIL(ING)Mark A Boyd, Basil Donovan
AIDS Research and Therapy|December 17, 2013
Antiretroviral regimens sparing agents from the nucleoside(tide) reverse transcriptase inhibitor class: a review of the recent literatureAmit C Achhra, Mark A Boyd
Lancet (London, England)|July 29, 2017
Long-acting injectable ART: next revolution in HIV?Mark A Boyd, David A Cooper
Lancet (London, England)|July 26, 2012
Optimisation of HIV care and service delivery: doing more with lessMark A Boyd, David A Cooper
Pharmacoeconomics|December 25, 2010
Clinical management of treatment-experienced, HIV/AIDS patients in the combination antiretroviral therapy eraMark A Boyd, Andrew M Hill
Lancet (London, England)|June 19, 2010
Operational research in HIV priority areas: the African wayMark A Boyd, Chidi A Nwizu
Pageof 10